{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:14:01Z","timestamp":1788984841247,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01884-x","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:38:25Z","timestamp":1786358305000},"page":"4683-4703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adherence to CAL\/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-0290","authenticated-orcid":false,"given":"Anthony","family":"Bewley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8816-1989","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"L\u00f3pez Estebaranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-2129","authenticated-orcid":false,"given":"Jordi","family":"Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-6486","authenticated-orcid":false,"given":"V\u00edctor","family":"Sapena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Koscielny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"6","key":"1884_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. https:\/\/doi.org\/10.3390\/ijms20061475.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1884_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.36849\/JDD.6498","volume":"21","author":"R Ghafoor","year":"2022","unstructured":"Ghafoor R, Patil A, Yamauchi P, et al. Treatment of scalp psoriasis. J Drugs Dermatol. 2022;21(8):833\u20137. https:\/\/doi.org\/10.36849\/JDD.6498.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1884_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-020-00099-7","volume":"20","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. https:\/\/doi.org\/10.1186\/s12895-020-00099-7.","journal-title":"BMC Dermatol"},{"key":"1884_CR4","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S85330","author":"M Gooderham","year":"2016","unstructured":"Gooderham M, Blakely K. Management of scalp psoriasis: current perspectives. Psoriasis Targets Ther. 2016. https:\/\/doi.org\/10.2147\/PTT.S85330.","journal-title":"Psoriasis Targets Ther"},{"issue":"6","key":"1884_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/reum.2018.80718","volume":"56","author":"K Dopytalska","year":"2018","unstructured":"Dopytalska K, Sobolewski P, B\u0142aszczak A, Szyma\u0144ska E, Walecka I. Psoriasis in special localizations. Rheumatology (Oxford). 2018;56(6):392\u20138. https:\/\/doi.org\/10.5114\/reum.2018.80718.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1884_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s13555-021-00521-z","volume":"11","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management. Dermatol Ther. 2021;11(3):769\u201397. https:\/\/doi.org\/10.1007\/s13555-021-00521-z.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1884_CR7","first-page":"309","volume":"150","author":"A Zampieron","year":"2015","unstructured":"Zampieron A, Buja A, Fusco M, et al. Quality of life in patients with scalp psoriasis. G Ital Dermatol E Venereol. 2015;150(3):309\u201316.","journal-title":"G Ital Dermatol E Venereol"},{"issue":"12","key":"1884_CR8","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jdv.14460","volume":"31","author":"J Koo","year":"2017","unstructured":"Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017;31(12):1999\u20132009. https:\/\/doi.org\/10.1111\/jdv.14460.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1884_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2133.2006.07405.x","volume":"155","author":"L Dubertret","year":"2006","unstructured":"Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155(4):729\u201336. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07405.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1884_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2340\/00015555-1731","volume":"94","author":"F Sampogna","year":"2014","unstructured":"Sampogna F, Linder D, Piaserico S, et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014;94(4):411\u20134. https:\/\/doi.org\/10.2340\/00015555-1731.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1884_CR11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jaad.2008.11.890","volume":"60","author":"CS Chan","year":"2009","unstructured":"Chan CS, Voorhees ASV, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2008.11.890.","journal-title":"J Am Acad Dermatol"},{"issue":"S1","key":"1884_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/jdv.18751","volume":"37","author":"A Bewley","year":"2023","unstructured":"Bewley A, van de Kerkhof P. Engaging psoriasis patients in adherence and outcomes to topical treatments: a summary from the Symposium \u2018Tailoring topical psoriasis treatments to patients\u2019 needs and expectations\u2019 of the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37(S1):9\u201313. https:\/\/doi.org\/10.1111\/jdv.18751.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1884_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2310\/7750.2011.10066","volume":"15","author":"K Papp","year":"2011","unstructured":"Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J, Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210\u20139. https:\/\/doi.org\/10.2310\/7750.2011.10066.","journal-title":"J Cutan Med Surg"},{"key":"1884_CR14","doi-asserted-by":"publisher","first-page":"e6712","DOI":"10.1136\/bmj.e6712","volume":"345","author":"E Samarasekera","year":"2012","unstructured":"Samarasekera E, Sawyer L, Parnham J, Smith CH, Guideline Development Group. Assessment and management of psoriasis: summary of NICE guidance. BMJ. 2012;345:e6712. https:\/\/doi.org\/10.1136\/bmj.e6712.","journal-title":"BMJ"},{"issue":"Suppl 2","key":"1884_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jdv.12443","volume":"28","author":"E Daud\u00e9n","year":"2014","unstructured":"Daud\u00e9n E, Bewley A, Lambert J, Girolomoni G, Cambazard F, Reich K. Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 2):22\u201332. https:\/\/doi.org\/10.1111\/jdv.12443.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1884_CR16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.087.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1884_CR17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1081\/ddc-200040297","volume":"30","author":"L Simonsen","year":"2004","unstructured":"Simonsen L, H\u00f8y G, Didriksen E, Persson J, Melchior N, Hansen J. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Ind Pharm. 2004;30(10):1095\u2013102. https:\/\/doi.org\/10.1081\/ddc-200040297.","journal-title":"Drug Dev Ind Pharm"},{"issue":"Suppl 3","key":"1884_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1468-3083.2005.01329.x","volume":"19","author":"S Fou\u00e9r\u00e9","year":"2005","unstructured":"Fou\u00e9r\u00e9 S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2\u20136. https:\/\/doi.org\/10.1111\/j.1468-3083.2005.01329.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"15","key":"1884_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154484","volume":"13","author":"P Gisondi","year":"2024","unstructured":"Gisondi P, Gracia-Caza\u00f1a T, Kurzen H, Galv\u00e1n J. Calcipotriol\/betamethasone dipropionate for the treatment of psoriasis: mechanism of action and evidence of efficacy and safety versus topical corticosteroids. J Clin Med. 2024;13(15):4484. https:\/\/doi.org\/10.3390\/jcm13154484.","journal-title":"J Clin Med"},{"issue":"2","key":"1884_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/jdv.17734","volume":"36","author":"A Pinter","year":"2022","unstructured":"Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M. A pooled analysis of randomized, controlled, phase\u00a03 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36(2):228\u201336. https:\/\/doi.org\/10.1111\/jdv.17734.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1884_CR21","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s13555-023-01003-0","volume":"13","author":"T Torres","year":"2023","unstructured":"Torres T, Galv\u00e1n J, Crutchley N, et al. Calcipotriol and betamethasone dipropionate cream based on PAD technology for the treatment of plaque psoriasis: a narrative review. Dermatol Ther. 2023;13(10):2153\u201369. https:\/\/doi.org\/10.1007\/s13555-023-01003-0.","journal-title":"Dermatol Ther"},{"key":"1884_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llag185","author":"JL L\u00f3pez Estebaranz","year":"2026","unstructured":"L\u00f3pez Estebaranz JL, Bewley A, Pinter A, Galv\u00e1n J, Koscielny V. Patient and clinician reported outcomes of calcipotriol\/betamethasone dipropionate PAD-cream for the treatment of adult patients with scalp psoriasis under real-world conditions: results from the prospective, non-interventional, multicentre PRO-SCALP study. Clin Exp Dermatol. 2026. https:\/\/doi.org\/10.1093\/ced\/llag185.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1884_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/1545109709352884","volume":"8","author":"SC Kalichman","year":"2002","unstructured":"Kalichman SC, Amaral CM, Swetzes C, et al. A simple single-item rating scale to measure medication adherence: further evidence for convergent validity. J Int Assoc Physicians AIDS Care. 2002;8(6):367\u201374. https:\/\/doi.org\/10.1177\/1545109709352884.","journal-title":"J Int Assoc Physicians AIDS Care"},{"issue":"6","key":"1884_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/1545109709352884","volume":"8","author":"SC Kalichman","year":"2009","unstructured":"Kalichman SC, Amaral CM, Swetzes C, et al. A simple single-item rating scale to measure medication adherence: further evidence for convergent validity. J Int Assoc Physicians AIDS Care. 2009;8(6):367\u201374. https:\/\/doi.org\/10.1177\/1545109709352884.","journal-title":"J Int Assoc Physicians AIDS Care"},{"issue":"9","key":"1884_CR25","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","volume":"20","author":"PC Baumgartner","year":"2018","unstructured":"Baumgartner PC, Haynes RB, Hersberger KE, Arnet I. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;20(9):1290. https:\/\/doi.org\/10.3389\/fphar.2018.01290.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1884_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1161\/01.hyp.2.6.757","volume":"2","author":"RB Haynes","year":"1980","unstructured":"Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertens. 1980;2(6):757\u201364. https:\/\/doi.org\/10.1161\/01.hyp.2.6.757.","journal-title":"Hypertens"},{"issue":"11","key":"1884_CR27","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1345\/aph.1K264","volume":"41","author":"DP Nau","year":"2007","unstructured":"Nau DP, Steinke DT, Williams LK, et al. Adherence analysis using visual analog scale versus claims-based estimation. Ann Pharmacother. 2007;41(11):1792\u20137. https:\/\/doi.org\/10.1345\/aph.1K264.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"1884_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/ijd.12645","volume":"54","author":"AN Naegeli","year":"2015","unstructured":"Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The worst itch numeric rating scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol. 2015;54(6):715\u201322. https:\/\/doi.org\/10.1111\/ijd.12645.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1884_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RGB Langley","year":"2015","unstructured":"Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator\u2019s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1):23\u201331. https:\/\/doi.org\/10.3109\/09546634.2013.865009.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"1884_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","volume":"50","author":"CS Carlin","year":"2004","unstructured":"Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859\u201366. https:\/\/doi.org\/10.1016\/j.jaad.2003.09.014.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1884_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archdermatol.2010.242","volume":"147","author":"JD Jensen","year":"2011","unstructured":"Jensen JD, Fujita M, Dellavalle RP. Validation of psoriasis clinical severity and outcome measures: searching for a gold standard. Arch Dermatol. 2011;147(1):95\u20138. https:\/\/doi.org\/10.1001\/archdermatol.2010.242.","journal-title":"Arch Dermatol"},{"key":"1884_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.6.803","author":"SC Chen","year":"2002","unstructured":"Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002. https:\/\/doi.org\/10.1001\/archderm.138.6.803.","journal-title":"Arch Dermatol"},{"issue":"6","key":"1884_CR33","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/jdv.12774","volume":"29","author":"K Reich","year":"2015","unstructured":"Reich K, Zschocke I, Bachelez H, et al. Efficacy of a fixed combination of calcipotriol\/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase\u00a0IV, multicenter, randomized, controlled, prospective study. J Eur Acad Dermatol Venereol. 2015;29(6):1156\u201363. https:\/\/doi.org\/10.1111\/jdv.12774.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 4","key":"1884_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1468-3083.2011.04060.x","volume":"25","author":"A Bewley","year":"2011","unstructured":"Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9\u201314. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04060.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1884_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jdermsci.2016.02.008","volume":"82","author":"A Teixeira","year":"2016","unstructured":"Teixeira A, Teixeira M, Almeida V, Torres T, Sousa Lobo JM, Almeida IF. Methodologies for medication adherence evaluation: focus on psoriasis topical treatment. J Dermatol Sci. 2016;82(2):63\u20138. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.02.008.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"1884_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2357618","volume":"35","author":"JL L\u00f3pez Estebaranz","year":"2024","unstructured":"L\u00f3pez Estebaranz JL, Kurzen H, Galv\u00e1n J. Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey. J Dermatol Treat. 2024;35(1):2357618. https:\/\/doi.org\/10.1080\/09546634.2024.2357618.","journal-title":"J Dermatol Treat"},{"key":"1884_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/CCID.S56673","volume":"7","author":"J Shepherd","year":"2013","unstructured":"Shepherd J, Taheri A, Feldman SR. Once-daily topical treatment for psoriasis: calcipotriene + betamethasone two-compound topical formulation. Clin Cosmet Investig Dermatol. 2013;7:19\u201322. https:\/\/doi.org\/10.2147\/CCID.S56673.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"1884_CR38","doi-asserted-by":"publisher","first-page":"420","DOI":"10.36849\/JDD.2021.5653","volume":"20","author":"L Stein Gold","year":"2021","unstructured":"Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A phase\u00a03, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol JDD. 2021;20(4):420\u20135. https:\/\/doi.org\/10.36849\/JDD.2021.5653.","journal-title":"J Drugs Dermatol JDD"},{"issue":"4","key":"1884_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/archderm.140.4.408","volume":"140","author":"SS Zaghloul","year":"2004","unstructured":"Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408\u201314. https:\/\/doi.org\/10.1001\/archderm.140.4.408.","journal-title":"Arch Dermatol"},{"issue":"23","key":"1884_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235589","volume":"10","author":"L Rudnicka","year":"2021","unstructured":"Rudnicka L, Olszewska M, Goldust M, et al. Efficacy and safety of different formulations of calcipotriol\/betamethasone dipropionate in psoriasis: gel, foam, and ointment. J Clin Med. 2021;10(23):5589. https:\/\/doi.org\/10.3390\/jcm10235589.","journal-title":"J Clin Med"},{"key":"1884_CR41","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2023-2-8","volume":"12","author":"N Garc\u00eda","year":"2023","unstructured":"Garc\u00eda N, Guir\u00f3 P, Galv\u00e1n J, et al. Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD technology for the treatment of plaque psoriasis on the skin and scalp. Drugs Context. 2023;12:2023-2-8. https:\/\/doi.org\/10.7573\/dic.2023-2-8.","journal-title":"Drugs Context"},{"issue":"6","key":"1884_CR42","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/jdv.12174","volume":"28","author":"A Bewley","year":"2014","unstructured":"Bewley A, Burrage DM, Ersser SJ, Hansen M, Ward C. Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. J Eur Acad Dermatol Venereol. 2014;28(6):763\u201370. https:\/\/doi.org\/10.1111\/jdv.12174.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1884_CR43","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1080\/09546634.2019.1675855","volume":"32","author":"MT Svendsen","year":"2021","unstructured":"Svendsen MT, Feldman SR, Tiedemann SN, S\u00f8rensen ASS, Rivas CMR, Andersen KE. Psoriasis patient preferences for topical drugs: a systematic review. J Dermatol Treat. 2021;32(5):478\u201383. https:\/\/doi.org\/10.1080\/09546634.2019.1675855.","journal-title":"J Dermatol Treat"},{"issue":"9","key":"1884_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14090865","volume":"14","author":"S Cipolla","year":"2024","unstructured":"Cipolla S, Catapano P, Bonamico AF, et al. Factors associated with anxiety, depression, and quality of life in patients with psoriasis: a cross-sectional study. Brain Sci. 2024;14(9):865. https:\/\/doi.org\/10.3390\/brainsci14090865.","journal-title":"Brain Sci"},{"issue":"2","key":"1884_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jvc2.379","volume":"3","author":"A Lo","year":"2024","unstructured":"Lo A, Lovell KK, Greenzaid JD, Oscherwitz ME, Feldman SR. Adherence to treatment in dermatology: literature review. JEADV Clin Pract. 2024;3(2):401\u201318. https:\/\/doi.org\/10.1002\/jvc2.379.","journal-title":"JEADV Clin Pract"},{"issue":"7","key":"1884_CR46","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s13555-025-01431-0","volume":"15","author":"M Perrussel","year":"2025","unstructured":"Perrussel M, Arakelyan Z. Management of persistent psoriasis lesions using calcipotriol\/betamethasone foam combitherapy: real-world evidence case series from France. Dermatol Ther. 2025;15(7):1973\u201383. https:\/\/doi.org\/10.1007\/s13555-025-01431-0.","journal-title":"Dermatol Ther"},{"key":"1884_CR47","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.2147\/PPA.S117006","volume":"10","author":"I Belinch\u00f3n","year":"2016","unstructured":"Belinch\u00f3n I, Rivera R, Blanch C, Comellas M, Liz\u00e1n L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357\u201367. https:\/\/doi.org\/10.2147\/PPA.S117006.","journal-title":"Patient Prefer Adherence"},{"key":"1884_CR48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/PTT.S519420","volume":"15","author":"M Ponikowska","year":"2025","unstructured":"Ponikowska M, Vellone E, Czapla M, Uchmanowicz I. Challenges psoriasis and its impact on quality of life: challenges in treatment and management. Psoriasis (Auckl). 2025;15:175\u201383. https:\/\/doi.org\/10.2147\/PTT.S519420.","journal-title":"Psoriasis (Auckl)"},{"issue":"5","key":"1884_CR49","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/ddg.15373","volume":"22","author":"C Mann","year":"2024","unstructured":"Mann C, Dreher M, Rothschmidt JN, Staubach P. Burden of impaired sleep and its improvement through topical treatment in psoriasis and atopic dermatitis. J Dtsch Dermatol Ges. 2024;22(5):655\u201363. https:\/\/doi.org\/10.1111\/ddg.15373.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"1884_CR50","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1590\/abd1806-4841.20164476","volume":"91","author":"G Kontochristopoulos","year":"2016","unstructured":"Kontochristopoulos G, Kouris A, Chantzaras A, Petridis A, Yfantopoulos J. Improvement of health-related quality of life and adherence to treatment with calcipotriol-betamethasone dipropionate gel in patients with psoriasis vulgaris. An Bras Dermatol. 2016;91(2):160\u20136. https:\/\/doi.org\/10.1590\/abd1806-4841.20164476.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"1884_CR51","doi-asserted-by":"publisher","first-page":"7529636","DOI":"10.1155\/dth\/7529636","volume":"2025","author":"T Torres","year":"2025","unstructured":"Torres T, Martorell A, Leal Filipe P, et al. Real-world impact of calcipotriol\/betamethasone dipropionate aerosol foam on quality of life in patients with plaque psoriasis: a prospective observational study. Dermatol Ther. 2025;2025(1):7529636. https:\/\/doi.org\/10.1155\/dth\/7529636.","journal-title":"Dermatol Ther"},{"key":"1884_CR52","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2147\/PPA.S230921","volume":"13","author":"NA Alsubeeh","year":"2019","unstructured":"Alsubeeh NA, Alsharafi AA, Ahamed SS, Alajlan A. Treatment adherence among patients with five dermatological diseases and four treatment types\u2014a cross-sectional study. Patient Prefer Adherence. 2019;13:2029\u201338. https:\/\/doi.org\/10.2147\/PPA.S230921.","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"1884_CR53","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaad.2022.02.019","volume":"87","author":"U Rakita","year":"2022","unstructured":"Rakita U, Kaundinya T, Silverberg JI. Assessment of adherence to skin care recommendations in clinical practice: a real-world observational study. J Am Acad Dermatol. 2022;87(5):1141\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2022.02.019.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1884_CR54","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/09546634.2018.1476652","volume":"30","author":"W Wang","year":"2019","unstructured":"Wang W, Qiu Y, Zhao F, Zhang F. Poor medication adherence in patients with psoriasis and a successful intervention. J Dermatol Treat. 2019;30(6):525\u20138. https:\/\/doi.org\/10.1080\/09546634.2018.1476652.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"1884_CR55","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1186\/s12889-019-7778-x","volume":"19","author":"C Bubak","year":"2019","unstructured":"Bubak C, Schaarschmidt ML, Sch\u00f6ben L, Peitsch WK, Schmieder A. Analyzing the value of an educational program for psoriasis patients: a prospective controlled pilot study. BMC Public Health. 2019;19(1):1535. https:\/\/doi.org\/10.1186\/s12889-019-7778-x.","journal-title":"BMC Public Health"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01884-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01884-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01884-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:23Z","timestamp":1788981683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01884-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1884"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01884-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anthony Bewley has consulted\/received travel bursaries or lecturing fees from Abbvie, Almirall, Galderma, Incyte, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi, UCB, served on advisory boards for UK patient advocacy organizations, is a board member of the European Academy of Dermatology and Venereology (EADV), participated in British Association of Dermatologists (BAD) guidelines committees, and is Treasurer of European Society for Dermatology and Psychiatry (ESDaP). Andreas Pinter has received honoraria as investigator and\/or has received speakers\u2019 honoraria and\/or has received grants and\/or has been an advisor for AbbVie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, GSK, Galderma, Hexal, Janssen, LEO-Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi-Genzyme, Schering-Plough, UCB Pharma and Zuellig Pharma. Jos\u00e9 Luis L\u00f3pez Estebaranz has received honoraria as a speaker\/member of the Advisory Board from Abbvie, Almirall, Bioderma, Celgene, Galderma, Isdin, Janssen Cilag, Leo Pharma, Lilly, Novartis and Viatris and speaker honoraria from InfectoPharma, Mylan and StreamedUp. Jordi Galv\u00e1n, V\u00edctor Sapena and Volker Koscielny are employees of Almirall S.A.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice. In Germany, the first ethics approval was obtained from the Ethics Committee of Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany (reference #2023-1145). In the United\u00a0Kingdom, Health Research Authority (HRA) and Health and Care Research Wales (HCRW) approvals were obtained. Integrated Research Application System (IRAS) project ID 326834, Research Ethics Committee (REC) reference #23\/LO\/0474. In Spain, the first ethics approval was obtained from the Clinical Research Ethics Committee (CEIC) of Arag\u00f3n, Aragonese Institute of Health Sciences (IACS), Biomedical Research Center of Arag\u00f3n (CIBA), Avda. San Juan Bosco, 13, 1st floor, 50009 Zaragoza, Spain (reference #EPA23\u2013018). Additional regional ethics approvals were obtained in Germany and Spain, as needed (Table\u00a0\n                      \n                      ). All patients provided written informed consent for participation prior to study enrolment and the use of their de-identified, anonymized, aggregated data and their case details (including photographs) for publication.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}